Keidel S, LeMotte P, Apfel C
Department of Dermatology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Mol Cell Biol. 1994 Jan;14(1):287-98. doi: 10.1128/mcb.14.1.287-298.1994.
The pleiotropic effects of retinoic acid on cell differentiation and proliferation are mediated by two subfamilies of nuclear receptors, the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Recently the synthetic retinoid Ro 41-5253 was identified as a selective RAR alpha antagonist. As demonstrated by gel retardation assays, Ro 41-5253 and two related new RAR alpha antagonists do not influence RAR alpha/RXR alpha heterodimerization and DNA binding. In a limited trypsin digestion assay, complexation of RAR alpha with retinoic acid or several other agonistic retinoids altered the degradation of the receptor such that a 30-kDa proteolytic fragment became resistant to proteolysis. This suggests a ligand-induced conformational change, which may be necessary for the interaction of the DNA-bound RAR alpha/RXR alpha heterodimer with other transcription factors. Our results demonstrate that antagonists compete with agonists for binding to RAR alpha and may induce a different structural alteration, suggested by the tryptic resistance of a shorter 25-kDa protein fragment in the digestion assay. This RAR alpha conformation seems to allow RAR alpha/RXR alpha binding to DNA but not the subsequent transactivation of target genes. Protease mapping with C-terminally truncated receptors revealed that the proposed conformational changes mainly occur in the DE regions of RAR alpha. Complexation of RAR beta, RAR gamma, and RXR alpha, as well as the vitamin D3 receptor, with their natural ligands resulted in a similar resistance of fragments to proteolytic digestion. This could mean that ligand-induced conformational changes are a general feature in the hormonal activation of vitamin D3 and retinoid receptors.
维甲酸对细胞分化和增殖的多效性作用是由两个核受体亚家族介导的,即维甲酸受体(RARs)和类视黄醇X受体(RXRs)。最近,合成类视黄醇Ro 41-5253被鉴定为一种选择性RARα拮抗剂。凝胶阻滞试验表明,Ro 41-5253和另外两种相关的新型RARα拮抗剂不影响RARα/RXRα异二聚体化和DNA结合。在有限的胰蛋白酶消化试验中,RARα与维甲酸或其他几种激动性类视黄醇的复合改变了受体的降解,使得一个30 kDa的蛋白水解片段对蛋白水解具有抗性。这表明存在配体诱导的构象变化,这可能是与DNA结合的RARα/RXRα异二聚体与其他转录因子相互作用所必需的。我们的结果表明,拮抗剂与激动剂竞争结合RARα,并可能诱导不同的结构改变,消化试验中较短的25 kDa蛋白片段对胰蛋白酶的抗性表明了这一点。这种RARα构象似乎允许RARα/RXRα与DNA结合,但不允许随后对靶基因的反式激活。用C端截短的受体进行蛋白酶图谱分析表明,所提出的构象变化主要发生在RARα的DE区域。RARβ、RARγ和RXRα以及维生素D3受体与它们的天然配体复合后,片段对蛋白水解消化具有类似的抗性。这可能意味着配体诱导的构象变化是维生素D3和类视黄醇受体激素激活的一个普遍特征。